Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma
Authors:
Open Access
- 1 August 2024
- journal article
- research article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 15 (4) , 1777-1788
Abstract
Background: Intrahepatic cholangiocarcinoma (iCCA) is a rare biliary tract cancer with increasing incidence and poor survival rates. This study aims to evaluate the incidence and survival trends of iCCA patients over 20 years using a national cancer database, and assess the temporal association between survival and landmark clinical trials. Methods: Data was extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Age-adjusted incidence rates (AAIRs) were calculated from 2000 to 2020. Overall survival was analyzed based on diagnosis time and disease stage. Subgroup analysis was performed for patients diagnosed between 2015 and 2020. Landmark clinical trials were reviewed to determine temporal changes in survival. Results: In this analysis of 28,918 iCCA patients, the AAIR increased from 0.49 per 100,000 in 2000 to 1.38 in 2020 [annual percent change (APC) 6.94, 95% confidence interval (CI): 6.32 to 7.56], with a notable decline from 2019 to 2020. Incidence rates overall displayed an uptrend course across subgroups divided by sex, race, age, and disease stage. The age-adjusted mOS improved from 5.28 months in 2000 to 9.3 months in 2013, then stabilized between 8.0–9.0 months after 2013. Using 2010 as a cutoff, when the ABC-02 trial was published, the decade-based mOS increased from 6.55 months in 2000–2010 to 9.06 months in 2010–2020. During 2015–2020, the overall mOS was 8.8 months, with mOS of 24.3, 12.1, and 5.4 months for local, regional, and distant stages, respectively. Conclusions: The study indicates a steady rise in iCCA incidence since 2000 across all subgroups. Survival rates improved since 2000 but stabilized after 2013, following the ABC-02 trial publication in 2010. The impact of more recent clinical trials on survival rates requires further analysis in the coming years.Keywords
This publication has 45 references indexed in Scilit:
- Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinomaEuropean Radiology, 2023
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket studyAnnals of Oncology, 2022
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 MutationJAMA Oncology, 2021
- 58P Intrahepatic cholangiocarcinoma (iCCA) hidden amongst the unknown: A retrospective analysis of cancer of unknown primary (CUP) cases from a tertiary cancer centreAnnals of Oncology, 2021
- Toripalimab: First Global ApprovalDrugs, 2019
- Secular Trends in the Incidence of Cholangiocarcinoma in the USA and the Impact of MisclassificationDigestive Diseases and Sciences, 2014
- Treatment and Prognosis for Patients With Intrahepatic CholangiocarcinomaJAMA Surgery, 2014
- Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-medicare databaseHepatology, 2011
- Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma in the United States: A Population-Based Case-Control StudyClinical Gastroenterology and Hepatology, 2007
- Risk factors for intrahepatic cholangiocarcinoma in a low‐risk population: A nationwide case‐control studyInternational Journal of Cancer, 2006